Alendronate induces gastric injury and delays ulcer healing in rodents

doi:10.1016/S0024-3205(97)01040-0

Life Sciences

Volume 62, Issue 1, 28 November 1997, Pages 77-91

https://doi.org/10.1016/S0024-3205(97)01040-0 Get rights and content

Abstract

Gastric ulceration associated with the use of NSAIDs is most frequently observed in elderly women, the same sector of society most likely to be receiving therapy for osteoporosis. As some anti-osteoporosis medications have been suggested to irritate the upper gastrointestinal mucosa, we evaluated the ability of one such drug, alendronate, to damage the gastric mucosa and to influence the severity and healing of gastric ulcers in rodents. The effects of alendronate on indomethacin-induced antral ulceration was evaluated in the rabbit, while effects on ulcer healing and on the formation of gastric erosions was evaluated in the rat. Effects of alendronate on gastric acid secretion, blood flow and prostaglandin synthesis were also evaluated. Alendronate caused erosions in the rabbit stomach, but not antral ulceration. However, at the highest doses tested (80 mg) alendronate increased the incidence and size of indomethacin-induced antral ulcers. Alendronate also enhanced indomethacin-induced gastric damage in the rat, and delayed gastric ulcer healing. These effects of alendronate were not attributable to changes in gastric acid secretion, blood flow, prostaglandin synthesis or the pharmacokinetics of indomethacin. The damaging effects of alendronate on the stomach were due to topical irritant effects and could be observed at concentrations as low as 4 mg/ml within 30 min of oral administration or topical superfusion. These results support preliminary clinical evidence that alendronate can damage the gastric mucosa. While gastric injury may be a rare occurrence in patients taking this drug, concomitant use of alendronate and NSAIDs may increase the incidence or severity of ulceration.

References (28)

R. Pounder
Gastroenterology
(1989)
S.N. Elliott et al.
Gastroenterology
(1995)
J.Y. Wang et al.
Gastroenterology
(1989)
D.M. Mccafferty et al.
Gastroenterology
(1995)
J.G.P. Ferraz et al.
Gastroenterology
(1995)
J.L. Wallace et al.
Gastroenterology
(1994)
L.J. Dusci et al.
J. Chromatogr.
(1979)
D.M. Black et al.
The Lancet
(1996)
S. Adami et al.
Bone
(1994)
J.L. Wallace
Gastroenterology
(1997)

J.H. Lin et al.

J. Pharmaceut. Sci.

(1994)

J.L. Wallace et al.

Gastroenterology

(1986)

N.H. Bell et al.

Am. J. Med.

(1994)

D.R. Lichtenstein et al.

Arthritis Rheum.

(1995)

Cited by (83)

New insights on physico-chemical investigation of bisphosphonate adsorption isotherm into apatite substrate using statistical physics treatment
2020, Journal of Molecular Liquids
In this paper, a well-crystallized hydroxyapatite (HA) and nanocrystalline apatites (NCA) were used to interpret the adsorption process of two bisphosphonates (BPs), namely Tiludronate (Tilu) and Risedronate (Rise). These BPs are among the most prescribed classes of drugs for the treatment of bone disorders disease, particularly Osteoporosis. The equilibrium data used to express the variation of uptake capacity as a function of concentration were determined by varying some experimental physicochemical conditions (e.g. temperature and pH). A preliminary analysis of all the adsorption isotherms obviously indicates that the adsorption quantity tends towards a saturation level. This suggests a finite number of adsorbed layers involved in the adsorption mechanisms. To give a reasonable analysis of the drug adsorption process, three advanced models are proposed and developed in the light of a statistical physics treatment which is tested and discussed. The modeling analysis reveals that the adsorption of the two drugs occurs by the formation of two different adsorbed layers on the apatite surface. Based on the analysis of the selected model parameters, it was deduced that both drugs molecules were anchored alternately with parallel and non-parallel positions on the apatite substrate. The study of the uptake capacities at saturation showed that these parameters followed the sequence: Q_asat (Rise-NCA) ˃ Q_asat (Rise-HA) ˃ Qasat (Tilu-HA), indicating that the NCA adsorbent was more effective for the Rise drug adsorption than the HA adsorbent. The estimated adsorption energies globally varied from 9.20 to 19.52 kJ/mol, confirming the physical nature of the adsorption process for the investigated systems. Conventionally, to characterize the adsorption process, the entropy (S_a), the enthalpy of Gibbs (G) and the internal energy (E_int) were treated and interpreted.
Reduced food interaction and enhanced gastrointestinal tolerability of a new system based on risedronate complexed with Eudragit E100: Mechanistic approaches from in vitro and in vivo studies
2016, European Journal of Pharmaceutics and Biopharmaceutics
Novel complexes consisting of Eudragit E100-risedronate are presented. The oral bioavailability of risedronate in rats was determined through its percentage excreted in urine after administration of complexed or free risedronate in fed and fasted conditions. The evaluation of the risedronate gastro-duodenal irritation potential was carried out by macroscopic and histological analyses in an experimental rat model. The degree of counterionic condensation between Eudragit E100 and risedronate was assessed by dialysis with, mechanistic information about the interaction with calcium and the release of risedronate from the complexes being obtained using physiological solution and simulated gastric fluid without pepsin. Non-significant differences were observed in the urinary excretion of risedronate when the complex or free risedronate was administered to fasted rats. However, the urinary excretion of risedronate in the complex group was 4-times higher than in the free risedronate group when animals were concomitantly administered with food. This behavior was related to the high degree of counterionic condensation in the complex (86.5%), which led to a reduction in the calcium induced rate and magnitude of risedronate precipitation and resulted in a decrease in the gastroduodenal damage from the complex, as evidenced by a lower frequency of gastric mucosae hemorrhage. A sustained release of risedronate from the complex was observed toward water, simulated gastric fluid or physiological solution, through an ionic-exchange mechanism. In conclusion, complexation with Eudragit E100 could be a useful strategy to overcome the unfavorable properties of risedronate.
Alendronate-calcium phosphate hybrid films promoted the osteoblast differentiation and inhibited osteoclastogenic activity
2015, Journal of Industrial and Engineering Chemistry
Citation Excerpt :
For the treatment of bone diseases, BPs are supplied via either oral administration or intravenous injection. These methods result in low absorption by body, less than 1–3% of administrated dosage [15], and can cause systemic side-effects including fever, throat or stomach ulcers [16,17]. In order to avoid unwanted side-effects while improving the efficacy of the drug, it will be desirable to develop alternate drug delivery systems which can maximize and sustain its effect while minimizing the drug dosage and side effects.
Surface property of biomaterials is a crucial factor determining the biocompatibility of a biomaterial. In this study, we aimed at evaluating the feasibility of alendronate (ALN) and CP hybrid films (CPAs) to promote bone regeneration. Experimental analysis elucidated that ALN incorporation promoted osteoblast proliferation and differentiation, phenotype gene expression, phase shift from differentiation into mineralization, and bone-like nodule formation. Inhibitory effect on the formation of multinucleated osteoclast was substantial. Therefore, the hybrid films can enhance osteogenic responses while inducing anti-osteoclastic effects. We expect the hybrid films can be potentially utilized for the promotion of bone regeneration.
Progress on the preparation of nanocrystalline apatites and surface characterization: Overview of fundamental and applied aspects
2013, Progress in Crystal Growth and Characterization of Materials
Citation Excerpt :
The classic BPs treatment is the systemic way by oral administration or intravenous injection. However, undesirable side-effects like fever [265], ulcers [266,267] or osteonecrosis of the jaw [267,268] are commonly observed by systemic use of BPs. Moreover low bioavailability is commonly observed for oral administration [269].
Nanocrystalline calcium phosphate apatites constitute the main inorganic part of hard tissues, and a growing focus is devoted to prepare synthetic analogs, so-called “biomimetic”, able to precisely mimic the morphological and physico-chemical features of biological apatite compounds. Both from fundamental and applied viewpoints, an accurate characterization of nanocrystalline apatites, including their peculiar surface features, and a deep knowledge of crystallization aspects are prerequisites to attempt understanding mineralization phenomena in vivo as well as for designing innovative bioactive materials that may then find applications in bone tissue engineering, either as self-supported scaffolds and fillers or in the form of coatings, but also in other domains such as drug delivery or else medical imaging. Also, interfacial phenomena are of prime importance for getting a better insight of biomineralization and for following the behavior of biomaterials in or close to their final conditions of use. In this view, both adsorption and ion exchange represent essential processes involving the surface of apatite nanocrystals, possibly doped with foreign elements or functionalized with organic molecules of interest. In this review paper, we will address these various points in details based on a large literature survey. We will also underline the fundamental physico-chemical and behavioral differences that exist between nanocrystalline apatites (whether of biological origin or their synthetic biomimetic analogs) and stoichiometric hydroxyapatite.
Bioceramics for drug delivery
2013, Acta Materialia
Bioceramics, such as calcium phosphate ceramics and cements and silica-based glasses, are widely used as components of implants for bone and teeth restoration. Nowadays, the advanced processing methods and new chemical strategies allow the incorporation of drugs within them or on their functionalized surfaces. In this regard, bioceramics act as local drug delivery systems to treat large bone defects, osteoporotic fractures, bone infections and bone tumours. The development of new mesoporous nanoceramics, suitable to be used as carriers for drug delivery, has also opened new perspectives for cancer therapies. Mesoporous silica nanoparticles can be prepared as vehicles able to release the drug within specific cancerous cells. When the pores are closed with molecular nanogates, stimuli-responsive systems can be obtained, thus allowing drug release at will by supplying external stimuli such as magnetic fields, ultrasound or light. The present review looks at the advances in the bioceramic drug delivery systems, as well as those nanoceramics intended for specific and controlled drug release.
Role of soluble guanylate cyclase activation in the gastroprotective effect of the HO-1/CO pathway against alendronate-induced gastric damage in rats
2013, European Journal of Pharmacology
Citation Excerpt :
Induction of phase II enzymes such as HO-1 renders cells more resistant to potential subsequent challenges of greater stress (Yeligar et al., 2010). In fact, alendronate has been shown to cause erosions and ulcers in rodents and human stomach and to interfere with the healing of pre-existing lesions (Elliott et al., 1998; Graham and Malaty, 1999; Wallace et al., 1999). The mechanism through which alendronate and other bisphosphonates cause mucosal injury has not been clearly identified.
Our objective was to evaluate the role of soluble guanylate cyclase (sGC) activation in the gastroprotective effect of the HO-1/CO pathway against alendronate-induced gastric damage in rats. Rats were pretreated, once daily for 4 days, with saline, hemin (HO-1 inducer), or dimanganese decacarbonyl (DMDC, CO donor). Another group received zinc protoporphyrin IX (ZnPP IX, HO-1 antagonist) 1 h before hemin treatment or sGC inhibitor (ODQ) 30 min before hemin and DMDC treatment. After 30 min, gastric damage was induced by alendronate (30 mg/kg) by gavage. On the last day of treatment, 4 h after alendronate administration, the animals were killed. Gastric lesions were measured using a computer planimetry program, and gastric corpus pieces were assayed for malondialdehyde (MDA), glutathione (GSH), pro-inflammatory cytokines (tumor necrosis factor [TNF]-α and interleukin [IL]-1β), myeloperoxidase (MPO), or bilirubin. Another group was used to measure gastric mucus. HO-1 expression was determined after saline or alendronate administration by immunohistochemistry. Alendronate induced gastric damage, produced neutrophil accumulation, increased MDA levels and MPO activity, and reduced GSH and mucus in the gastric tissue. Alendronate also increased HO-1 immunoreactivity and the level of bilirubin in gastric mucosa. Pretreatment with hemin or DMDC reduced neutrophil infiltration and TNF-α, IL-1β, and MDA formation, and increased the levels of GSH and mucus in the gastric tissue. ODQ completely abolished the gastroprotective effect of hemin and DMDC and increased alendronate gastric damage. Our results suggest that the HO-1/CO pathway plays a protective role against alendronate-induced gastric damage through mechanisms that can be dependent on sGC activation.

View all citing articles on Scopus

View full text

Alendronate induces gastric injury and delays ulcer healing in rodents

Abstract

Gastroenterology

Gastroenterology

Gastroenterology

Gastroenterology

Gastroenterology

Gastroenterology

J. Chromatogr.

The Lancet

Bone

Gastroenterology

J. Pharmaceut. Sci.

Gastroenterology

Am. J. Med.

Arthritis Rheum.